Navigation Links
Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
Date:5/18/2009

In August 2006, Schering-Plough and Novartis announced an agreement for the joint worldwide development and commercialization of a fixed-dose combination treatment containing Schering-Plough's mometasone furoate and Novartis' indacaterol. Indacaterol is currently under regulatory review in the U.S. and European Union.

About asthma and COPD

Asthma is a chronic inflammatory lung disease that affects 300 million people worldwide, with an estimated 15 million suffering from a severe form of the disease.(2) Their health and quality of daily life are often severely affected, and more than 180,000 people die from asthma each year throughout the world.(3)

COPD, the world's fourth most common cause of death, is an irreversible and chronic obstruction of the airways, which is caused primarily by smoking. It is estimated that the disease is prevalent in 4 percent of the population in the USA, Europe and Japan, and that at least one in 15 smokers suffers from COPD. COPD progresses slowly and eventually leads to a largely irreversible loss of lung function.

About ASMANEX

ASMANEX is approved for the maintenance treatment of asthma in patients 4 years of age and older. ASMANEX will not relieve sudden asthma symptoms and is not for children less than 4 years of age.

In the U.S., it is available in two dose strengths, 110 mcg for children between 4 and 11 years old, and 220 mcg for patients 12 and older.

Important Safety Information

ASMANEX is not a rescue inhaler and should not be used to treat sudden asthma symptoms. Use a rescue inhaler to relieve sudden asthma symptoms.

ASMANEX should not be used to treat acute asthma episodes (including status asthmaticus) where extra measures are required.

ASMANEX is not for patients who have a hypersensitivity (including allergic reactions) to mometasone or any of the in
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Schering-Plough Schedules Webcast For Annual Meeting of Shareholders
2. Schering-Plough Schedules Conference Call Webcast for 2009 First Quarter Earnings
3. Schering-Plough to Webcast Presentation at Barclays Capital Global Healthcare Conference
4. Video: Schering-Plough Introduces AFRIN(R) PureSea(TM): A Natural, Gentle Nasal Rinse From the Seas of Northern France
5. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
6. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
7. Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
8. Schering-Plough to Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
9. HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China
10. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
11. Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 19, 2014 The Asia-Pacific Speech Analytics ... in Asia-Pacific with analysis and forecast of revenue. This ... 2014 to $208 million by 2019, at a Compound ... 2019. , Browse through the TOC of the Asia-Pacific ... the in-depth analysis provided. It also provides a glimpse ...
(Date:10/19/2014)... The report "Unmanned Ground Vehicle Market by Application ... & by Geography - Forecasts & Analysis 2014–2020", ... market into various sub segments with an in-depth ... also identifies the factors driving this market, various ... adoption trends. , The unmanned ground vehicle market ...
(Date:10/18/2014)... 18, 2014 The Asia-Pacific Bio-based ... segments the bio-based advanced phase change material market ... , Browse through the TOC of the Asia-Pacific ... get an idea of the in-depth analysis provided. ... in the Asia-Pacific bio-based advanced phase change material ...
(Date:10/18/2014)... Asia-Pacific hardware encryption display market report defines and segments ... of revenue. This market was valued $5,154.0 million in ... 2018, at a CAGR of 58.4% from 2013 to ... hardware encryption market report, to get an idea of ... of the segmentation of the market, and is supported ...
Breaking Biology Technology:The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 2Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 5The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 4The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3
... Primary Endpoint Data from Phase II Study Shows 71% Objective ... - , , - Secondary Endpoint Evaluation Shows Promising ... - , , ORLANDO, Fla. and TUSTIN, Calif., June ... today announced that preliminary results from a Phase II trial ...
... Presented Today at American Society of Clinical Oncology , ... Inc. today presented data demonstrating the use of ChemoFX(R), ... (ERBITUX(R)) on the colorectal cancer cells of individual patients. ... 54 primary colorectal cultures tested, eight percent were responsive ...
... 1 PTC Therapeutics, Inc. (PTC) today announced that ... Commercial Operations. In this role, she will report ... be responsible for PTC,s patient services and distribution functions ... (Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ) ...
Cached Biology Technology:Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 3Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 4Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 6Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3PTC Therapeutics Appoints Clare Kennedy as Vice President of Commercial Operations 2
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... edge technologies including Wocket™, the Smart Wallet, at the ... FiRe is a leading global conference on the intersection ... by Mark Anderson , founder and publisher of ...
(Date:10/15/2014)... risk from strains of influenza virus increases with the ... become complacent that the most substantial threats have been ... pandemics arise when a new virus strain – against ... spreads in the human population. There have been five ... of which – the 1918 Spanish Flu – cost ...
(Date:10/15/2014)... Gutenberg University Mainz (JGU) as a full member, ... maintain a significant nationwide standing in the field ... Johannes Gutenberg University Mainz as a full member ... national and international competition for the best minds ... be proud that Mainz University has been recognized ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... nice piece of certified sustainable fish at the supermarket, you,d ... aren,t always what they seem, according to researchers who have ... report their findings in the August 23 issue of ... found that, for fish purchased in US groceries, not all ...
... 2011, 3:00 PM U.S. EASTERN TIME) A study ... Sciences (PNAS) documents the success of a Wildlife ... to improve rural livelihoods while restoring local wildlife populations., ... began in Zambia in 2003 and has resulted in ...
... Research (ONR) will share partnership possibilities with members of ... Gold Coast Small Business Opportunity Conference, being held Aug. ... to identify potential program participants from among the 1,500 ... Small Business Programs. "The event is a great way ...
Cached Biology News:Eco-labeled seafood is not always what it seems 2Study confirms food security helps wildlife 2
The Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 6 microcentrifuge tubes....
...
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: